Beta-thalassemia is an inherited blood disorder characterized by chronic anemia, ineffective erythropoiesis, and in its most severe form, lifelong transfusion dependence. The standard of care for transfusion-dependent thalassemia (TDT) is regular red blood cell transfusions to relieve anemia and suppress ineffective erythropoiesis, and iron chelation therapy to mitigate morbidity and mortality related to iron overload. Allogeneic hematopoietic stem cell transplantation is a curative option but is only available to patients with an appropriate donor and carries risks of graft-versus-host disease and other transplant-related morbidity. In recent years, the therapeutic landscape for TDT has changed dramatically with the approval of two autologous gene therapies in the United States: betibeglogene autotemcel (beti-cel) and exagamglogene autotemcel (exa-cel). Clinical trials for both gene therapies have demonstrated high rates of sustained transfusion independence for both pediatric and adult age groups. However, despite these advances, challenges remain. Gene therapy requires myeloablative busulfan-based conditioning chemotherapy, which carries the risk of short- and long-term toxicities. Furthermore, centralized manufacturing and high treatment costs are likely to limit access to gene therapy. In this review, we discuss the available clinical trial and real-world data for beti-cel and exa-cel, and describe how gene therapy fits into the current treatment landscape, introducing areas of ongoing investigation to improve access to transformative therapy for TDT. Update on beta-thalassemia treatments: Focus on Gene therapy. Beta-thalassemia is caused by mutations in the beta-globin gene that lead to decreased hemoglobin levels (anemia). People with transfusion-dependent beta-thalassemia (TDT) require lifelong blood transfusions to treat their anemia and related complications. Because chronic blood transfusion therapy causes iron buildup in the body, patients also must receive long-term iron chelation therapy.